Engrail Therapeutics Inc.
- Address
- 12750 High Bluff Drive Suite 190
Sponsor Overview
Specializations
Neurology and Epilepsy
Engrail Therapeutics Inc. supports clinical research in focal epilepsy, with an emphasis on patients experiencing partial onset seizures. Its trial activity includes evaluation of adjunctive treatments for seizure control in people already receiving antiseizure therapy.
- Focal (partial onset) seizures
- Adjunctive antiseizure treatment
- Seizure frequency and control
The sponsor’s epilepsy-focused studies are centered on improving management options for individuals with persistent seizures despite standard treatment.
Psychiatry and Mood Disorders
The company also funds research in major depressive disorder, reflecting interest in clinical development for psychiatric conditions affecting mood, motivation, and daily functioning.
- Major depressive disorder
- Mood symptom relief
- Psychiatric therapeutic development
This area places the sponsor within research on treatments for persistent depressive symptoms and related functional impairment.
Adjunctive Treatment in Antiseizure Therapy
Engrail Therapeutics Inc. is involved in studies examining therapies used alongside existing antiseizure medications, with attention to patients receiving multiple background treatments.
- Combination treatment approaches
- Background antiseizure medication use
- Treatment-resistant seizure management
These studies address clinical needs in patients who require additional options beyond established seizure medicines.
Central Nervous System Drug Development
The sponsor’s portfolio extends across central nervous system research, including candidate therapies designed for neurological and psychiatric indications.
- Neurological therapeutics
- Psychiatric therapeutics
- Clinical development in CNS disorders
Its active trial presence across multiple sites and countries supports clinical investigation in disorders of the brain and nervous system.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of ENX-104 in a Single Ascending Dose Study for Patients with Major Depressive Disorder |  The Netherlands | Not Recruiting |
| The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in patients with focal (partial onset) seizures |  Belgium Germany Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 13 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders1 trial150 other sponsors
- 2.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
13 centres- Address
- Zernikedreef 8, 2333 CL Leiden
- Address
- Achterweg 3, 2103 SW Zwolle
- Address
- Villarroel 170, Department of Psychiatry and Psychology, Neuroscience Institute, 08036 Barcelona
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Maraweg 21, Gadderbaum, 33617 Bielefeld
- Address
- Calle La Maso 38, 28035 Madrid
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Engrail Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.